salix

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares gained 2 percent Monday morning after the company confirmed the Food and Drug Administration approved its bowel-cleansing preparation product. What Happened Valeant said the FDA granted approval for PLENVU, the company's polyethylene...

The catchphrase for investors has to be "Mind your Ks and Qs." For those of you wracking your brains over this, it is nothing but a call to focus on the 10-K and 10-Q reports companies file with the SEC. Related Link: 8-Ks, 10-Qs And 10-Ks: How Investors Use SEC Filings What Do 10-K And 10-Q...

"Fake news" strikes again — and this time spooks Valeant Pharmaceuticals Intl Inc (NYSE: VRX) investors. Shares fell 5 percent Wednesday afternoon following a Reuters report "announcing" the SEC’s investigation of Salix for possible securities law violations. However...

Pershing Square Capital Management, a major investment holding company managed by billionaire Bill Ackman, released on Wednesday its quarterly letter to investors. Net of all fees, the fund returned 2.9 percent in the third quarter and is lower by 13.5 percent since the start of 2016. By comparison...

Pershing Square Holding, the hedge fund controlled by billionaire Bill Ackman, once more brought home a bad report card. Monthly portfolio update issued by the company for October showed that net performance of the fund was down 22.5 percent in the year-to-date period. This is despite the broader...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is reportedly shopping for buyers to acquire its Salix unit for an expected $8.5 billion and additional royalty payments in the future. Valeant is plagued with debt, causing some concern among shareholders so any cash infusion would certainly ease...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) soared Tuesday after The Wall Street Journal reported the company is in talks to sell its Salix unit for up to $10 billion. Salix, a leader in the gastrointestinal market, was acquired by Valeant back in February 2015 for $158 per share,...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) crashed more than $5 per share on Tuesday. The stock didn't get much relief on Wednesday. After trading down more than 2 percent most of the day, Mizuho came out with a mid-day note on the struggling pharmaceutical company. The firm cuts its...

The Wall Street Journal reported late Thursday afternoon that prior to hiring Joseph Papa as CEO, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) received an acquisition proposal from Japan's Takeda Pharmaceutical and private equity firm TPG. The Wall Street Journal, citing "people familiar with the...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is facing an undisclosed SEC investigation, according to a report by Probes Reporter, an independent publisher of investment research that focuses on public company interactions with the SEC, Probes Reporter noted that it received a letter dated...

U.S. markets rose sharply after the U.S. government reported that 248,000 jobs were created in September, bringing the unemployment rate to 5.9 percent, the lowest it has been since July 2008. In addition to the jobs report, data from the U.S. government showed the trade deficit narrowing in...